Pharma Consulting Group (PCG)

Belkins
We are The Pharma Consulting Group. A leading provider of search, contingent and contract recruitment across the life sciences sector. We have expanded organically and through acquisition and in doing so have developed a business with the experience, networks and skill to deliver for you; whether you’re looking for a new member of your team, or a new challenge in your career.

Related News

BUSINESS INSIGHTS

WITH VEEVA ECONSENT, CELERION IS CHANGING THE CONSENT EXPERIENCE FOR CLINICS AND PATIENTS

Veeva Systems | October 07, 2021

news image

Veeva Systems (NYSE: VEEV ) announced that Celerion has launched Veeva eConsent , a MyVeeva for Patients solution, to provide electronic consent for its Phase I clinical trials obtain. With Veeva eConsent, Celerion is moving from manual and paper-based consent forms to a fully digital process. The company uses Veeva eConsent for several studies and has already given their consent to more than 200 test subjects. Covid-19 limited the time we cou...

Read More

EPIGENETIC CHANGES MAKE BREAST CANCER CELLS DRUG RESISTANT

LabRoots | January 20, 2020

news image

Changes in the epigenetics - the modifiable chemical tags that can change the genome and gene expression - of breast cancer cells can make them resistant to drugs that are targeting them. This seems to happen to ER+ breast cancer cells, which make up around two of every three cases of breast cancer. This type of cancer can become resistant to the hormonal therapy used to treat it. Breast cancer relapse could be reduced, researchers suggested, if these epigenetic changes can be reversed. Re...

Read More

PHARMACY MARKET

IQVIA AND NRX PHARMACEUTICALS COLLABORATE ON POTENTIAL MEDICAL SUPPORT FOR NOVEL COVID-19 TREATMENT

IQVIA™ | September 14, 2021

news image

IQVIA™ , a leading global provider of advanced analytics, technology solutions and clinical research services to the life sciences industry, today announced a transformative collaboration with NRx Pharmaceuticals (NRx). NRx is a company dedicated to creating innovative, life-saving treatments and bringing hope to those facing life-altering conditions with no approved disease-modifying therapies or cures. IQVIA is excited to collaborate with NRx as its designated partner, to provide pharmac...

Read More

PHARMACY MARKET

PFIZER AND BIONTECH ANNOUNCE SUBMISSION OF INITIAL DATA TO U.S. FDA TO SUPPORT BOOSTER DOSE OF COVID-19 VACCINE

Pfizer | August 17, 2021

news image

Pfizer Inc. and BioNTech SE today announced that they have submitted Phase 1 data to the U.S. Food and Drug Administration (FDA) to support the evaluation of a third, or booster, dose of the companies’ COVID-19 vaccine (BNT162b2) for future licensure. These data also will be submitted to the European Medicines Agency (EMA) and other regulatory authorities in the coming weeks. “The data we’ve seen to date suggest a third dose of our vaccine elicits antibody levels...

Read More

BUSINESS INSIGHTS

Veeva Systems | October 07, 2021

news image

WITH VEEVA ECONSENT, CELERION IS CHANGING THE CONSENT EXPERIENCE FOR CLINICS AND PATIENTS

Veeva Systems (NYSE: VEEV ) announced that Celerion has launched Veeva eConsent , a MyVeeva for Patients solution, to provide electronic consent for its Phase I clinical trials obtain. With Veeva eConsent, Celerion is moving from manual and paper-based consent forms to a fully digital process. The company uses Veeva eConsent for several studies and has already given their consent to more than 200 test subjects. Covid-19 limited the time we cou...

Read More

LabRoots | January 20, 2020

news image

EPIGENETIC CHANGES MAKE BREAST CANCER CELLS DRUG RESISTANT

Changes in the epigenetics - the modifiable chemical tags that can change the genome and gene expression - of breast cancer cells can make them resistant to drugs that are targeting them. This seems to happen to ER+ breast cancer cells, which make up around two of every three cases of breast cancer. This type of cancer can become resistant to the hormonal therapy used to treat it. Breast cancer relapse could be reduced, researchers suggested, if these epigenetic changes can be reversed. Re...

Read More

PHARMACY MARKET

IQVIA™ | September 14, 2021

news image

IQVIA AND NRX PHARMACEUTICALS COLLABORATE ON POTENTIAL MEDICAL SUPPORT FOR NOVEL COVID-19 TREATMENT

IQVIA™ , a leading global provider of advanced analytics, technology solutions and clinical research services to the life sciences industry, today announced a transformative collaboration with NRx Pharmaceuticals (NRx). NRx is a company dedicated to creating innovative, life-saving treatments and bringing hope to those facing life-altering conditions with no approved disease-modifying therapies or cures. IQVIA is excited to collaborate with NRx as its designated partner, to provide pharmac...

Read More

PHARMACY MARKET

Pfizer | August 17, 2021

news image

PFIZER AND BIONTECH ANNOUNCE SUBMISSION OF INITIAL DATA TO U.S. FDA TO SUPPORT BOOSTER DOSE OF COVID-19 VACCINE

Pfizer Inc. and BioNTech SE today announced that they have submitted Phase 1 data to the U.S. Food and Drug Administration (FDA) to support the evaluation of a third, or booster, dose of the companies’ COVID-19 vaccine (BNT162b2) for future licensure. These data also will be submitted to the European Medicines Agency (EMA) and other regulatory authorities in the coming weeks. “The data we’ve seen to date suggest a third dose of our vaccine elicits antibody levels...

Read More